Reviva Pharmaceuticals and Tenzing Acquisition today announced the completion of their business combination. Shares will trade on the Nasdaq starting Dec. 15 under RVPH for its common stock and RVPHW for its warrants.
The deal gives the combined company a valuation of $119 million.
California-based Reviva is a clinical-stage pharmaceutical company developing therapies to address medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Read more.
